CA 27-29 in patients with breast cancer with pulmonary fibrosis
4.9 (662) In stock
A series of 4 patients with breast cancer who have persistent elevation in CA 27.29 are reported, finding that false-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Cancer antigen (CA) 27-29, which is expressed on most carcinoma cells, is a soluble form of glycoprotein MUC1. It is overexpressed in tumors involving glandular epithelial cells, such as breast tumors. Measurement of CA 27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in patients with breast cancer. Although serial determination of tumor markers after primary treatment for breast cancer can preclinically detect recurrent/metastatic disease with lead times of approximately 2-9 months, the clinical value of this lead time remains to be determined. False-positive results might be observed in certain patients with no evidence of malignant disease, such as benign breast disease, ovarian cysts, and liver disease. Herein, we report a series of 4 patients with breast cancer (2 patients with interstitial lung fibrosis and 2 patients with nonspecific fibrotic lung changes) who have persistent elevation in CA 27.29 (normal, <38 U/mL).
Cancer Treatment-Related Lung Injury
CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis
Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges - ScienceDirect
Comparison of the diagnostic performances of circulating tumor cells and the serum tumor markers CEA, CA125, and CA15-3 for breast cancer: a retrospective case-control study
CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis
PDF) CA 27-29 in Patients with Breast Cancer with Pulmonary Fibrosis
Tumor Markers for Breast Cancer: Benefits, Drawbacks, Results & More
PDF] Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
PDF) Pneumonitis and pulmonary fibrosis associated with breast cancer treatments
Dr. Mudussara A. Khan, MD, Daytona Beach, FL, Oncologist
PDF) Evaluation of Tumor Markers In Asthma Patients
A Retrospective Analysis of Dose Distribution and Toxicity in Patients
Dr. Maurice R. Grant, MD, Morgantown, WV, Pathologist
Dr. Mudussara A. Khan, MD, Daytona Beach, FL, Oncologist
District 27 Details California State Assembly
For sale: 27 MAHONY AVE S, Hamilton, Ontario L8H3C3 - X8157922
CA27- CA 27-29, MARCADORES TUMORAIS
- Black Hoodie CORE MONOLOGO SWEATSHIRT Calvin Klein, Women
- Women Flowy Pleated Tank Tops Camisole with Built in Bra Sleeveless Summer Vest
- SHYAWAY Susie Everyday Bras - Padded Wirefree Demi Coverage (Pack
- Sweet deals Panties and stockings
- Buy Knee Brace - Prevent 100 Knee Support Online
- Oeko-Tex Certification Guide